Lorcaserin has demonstrated effective weight-loss properties after review of clinical trials and has been approved for use in individuals who are either obese or overweight and afflicted with at least one comorbidity associated with increased health risks (Hurren and Berlie, 2011). There have been three primary clinical trials to test the efficacy and safety of lorcaserin for weight loss. Two of the clinical trials were in individuals without diabetes and one in individuals with T2 diabetes (Golden, 2017). After one year, 47.1% of individuals without diabetes and 37.5% of those with diabetes reported 5% weight loss when taking lorcaserin as prescribed (10mg twice daily). Data collected from clinical trials since lorcaserin has been on the market have shown consistently that if it is used as prescribed in the intended population of individuals, lorcaserin has an acceptable safety record and minimal aversive reactions in accordance with the FDA (Greenway et al., 2016). According to clinical data, some of the most common reported side effects of lorcaserin include hypoglycemia, headaches, back pain, fatigue, and upper respiratory tract infections (Wishart et al., 2017). There have been some reports that lorcaserin causes some side effects related to perception and cognition (i.e., paraesthesia, hypoaesthesia, memory impairment, and amnesia; Greenway et al., 2016), though these particular side effects are considered rare. Drug Interactions There are hundreds of known interactions of lorcaserin with various drugs, most of which involve metabolic effects via inhibition of certain subtypes of P450 enzymes in the liver (Wishart et al., 2017). For example, Lorcaserin inhibits CYP2D6-mediated metabolism. After 4 days of simultaneous administration of lorcaserin and dextromethorphan, a cough suppressant metabolized by CYP2D6 in the liver, dextromethorphan concentrations increased by ~76%. Little is known about the safety or the efficacy of taking lorcaserin in conjunction with other weight-loss medication. Taking lorcaserin with other serotonergic drugs such as SSRIs, MAOIs, triptans, and bupropion can be dangerous (Golden, 2017). ConclusionLorcaserin is a highly selective 5-HT2C receptor agonist that facilitates weight loss via appetite suppression without the dangerous side effects seen in previous weight loss drugs due to its low affinity to serotonin receptor subtypes 2A and 2B. Though potentially controversial since its efficacy and safety has been reported in only three large clinical trials, it appears to be a viable option for weight management in individuals who have not had success using more traditional weight-loss methods. Furthermore, its exact mechanism of action is still somewhat hypothetical and remains to be elucidated.